Vascular endothelial growth factor gene polymorphisms in ovarian cancer

Gynecologic Oncology

Volumn 105, Issue 2, 2007, Pages 385-389

  Polterauer, Stephan ^a   Grimm, Christoph ^a   Mustea, Alexander ^b   Concin, Nicole ^c   Tanner, Berno ^d   Thiel, Falk ^e   Heinze, Georg ^a   Reinthaller, Alexander ^a   Zeillinger, Robert ^a,f   Hefler, Lukas A ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^f LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

Gene; Ovarian cancer; Polymorphism; Prognosis; VEGF

Indexed keywords

VASCULOTROPIN;

ADULT; ANGIOGENESIS; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CAUCASIAN; FEMALE; GENE; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HAPLOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; UNIVARIATE ANALYSIS; VEGF GENE;

AGED; FEMALE; GENOTYPE; HUMANS; LINKAGE DISEQUILIBRIUM; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; POLYMORPHISM, GENETIC; PROGNOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34247200589     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.12.021     Document Type: Article

References (32)

1. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat. Med. 9 (2003) 669-676
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid, and other disease. Nat. Med. 1 (1995) 27-31
3. Tempfer C., Obermair A., Hefler L., Haeusler G., Gitsch G., and Kainz C. Vascular endothelial growth factor serum concentrations in ovarian cancer. Obstet. Gynecol. 92 (1998) 360-363
4. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
5. Tischer E., Mitchell R., Hartman T., Silva M., Gospodarowicz D., Fiddes J.C., et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. 266 (1991) 11947-11954
6. Neufeld G., Cohen T., Gitay-Goren H., Poltorak Z., Tessler S., Sharon R., et al. Similarities and differences between the vascular endothelial growth factor (VEGF) splice variants. Cancer Metastasis Rev. 15 (1996) 153-158
7. Ferrara N., and Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 18 (1997) 4-25
8. Lin C.C., Wu H.C., Tsai F.J., Chen H.Y., and Chen W.C. Vascular endothelial growth factor gene - 460 C/T polymorphism is a biomarker for prostate cancer. Urology 62 (2003) 374-377
9. Jacobs E.J., Feigelson H.S., Bain E.B., Brady K.A., Rodriguez C., Stevens V.L., et al. Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Res. 8 (2006) R22 [Electronic publication 2006]
10. Goodheart M.J., Ritchie J.M., Rose S.L., Fruehauf J.P., De Young B.R., and Buller R.E. The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer. Clin. Cancer Res. 11 (2005) 3733-3742
11. Kim E.J., Jeong P., Quan C., Kim J., Bae S.C., Yoon S.J., et al. Genotypes of TNF-alpha, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer. Urology 65 (2005) 70-75
12. Vincenti V., Cassano C., Rocchi M., and Persico G. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 93 (1996) 1493-1495
13. Watson C.J., Webb N.J., Bottomley M.J., and Brenchley P.E. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12 (2000) 1232-1235
14. Stevens A., Soden J., Brenchley P.E., Ralph S., and Ray D.W. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res. 63 (2003) 812-816
15. Renner W., Kotschan S., Hoffmann C., Obermayer-Pietsch B., and Pilger E. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J. Vasc. Res. 37 (2000) 443-448
16. Summers A.M., Coupes B.M., Brennan M.F., Ralph S.A., Short C.D., and Brenchley P.E. VEGF - 460 genotype plays an important role in progression to chronic kidney disease stage 5. Nephrol. Dial Transplant 20 (2005) 2427-2432
17. Hsieh Y.Y., Chang C.C., Tsai F.J., Yeh L.S., Lin C.C., and Peng C.T. T allele for VEGF gene - 460 polymorphism at the 5′-untranslated region: association with a higher susceptibility to endometriosis. J. Reprod. Med. 49 (2004) 468-472
18. Medford A.R., Keen L.J., Bidwell J.L., and Millar A.B. Vascular endothelial growth factor gene polymorphism and acute respiratory distress syndrome. Thorax 60 (2005) 244-248
19. van der Meer P., De Boer R.A., White H.L., van der Steege G., Hall A.S., Voors A.A., et al. The VEGF + 405 CC promoter polymorphism is associated with an impaired prognosis in patients with chronic heart failure: a MERIT-HF substudy. J. Card. Failure 11 (2005) 279-284
20. Banyasz I., Szabo S., Bokodi G., Vannay A., Vasarhelyi B., Szabo A., et al. Genetic polymorphisms of vascular endothelial growth factor in severe pre-eclampsia. Mol. Hum. Reprod. 12 (2006) 233-236
21. Krippl P., Langsenlehner U., Renner W., Yazdani-Biuki B., Wolf G., Wascher T.C., et al. A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int. J. Cancer 106 (2003) 468-471
22. Poon R.T., Fan S.T., and Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J. Clin. Oncol. 19 (2001) 1207-1225
23. Chomczynski P., Mackey K., Drews R., and Wilfinger W. DNAzol: a reagent for the rapid isolation of genomic DNA. Biotechniques 22 3 (1997) 550-553
24. Speiser P., Gharehbaghi-Schnell E., Eder S., Haid A., Kovarik J., Nenutil R., et al. A constitutional de novo mutation in exon 8 of the p53 gene in a patient with multiple primary malignancies. Br. J. Cancer 74 (1996) 269-273
25. Abu-Jawdeh G.M., Faix J.D., Niloff J., Tognazzi K., Manseau E., Dvorak H.F., et al. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab. Invest. 74 (1996) 1105-1115
26. Mu J., Abe Y., Tsutsui T., Yamamoto N., Tai X.G., Niwa O., et al. Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity. Jpn. J. Cancer Res. 87 (1996) 963-971
27. Nakanishi Y., Kodama J., Yoshinouchi M., Tokumo K., Kamimura S., Okuda H., et al. The expression of vascular endothelial growth factor and transforming growth factor-beta associates with angiogenesis in epithelial ovarian cancer. Int. J. Gynecol. Pathol. 16 (1997) 256-262
28. Hefler L.A., Grimm C., Ackermann S., Malur S., Radjabi-Rahat A.R., Leodolter S., et al. An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer. Cancer Res. 63 (2003) 3066-3068
29. Hefler L.A., Ludwig E., Lebrecht A., Zeillinger R., Tong-Cacsire D., Koelbl H., et al. Polymorphisms of the interleukin-1 gene cluster and ovarian cancer. J. Soc. Gynecol. Invest. 9 (2002) 386-390
30. Fallows S., Price J., Atkinson R.J., Johnston P.G., Hickey I., and Russell S.E. P53 mutation does not affect prognosis in ovarian epithelial malignancies. J. Pathol. 194 (2001) 68-75
31. Cohn D.E., Valmadre S., Resnick K.E., Eaton L.A., Copeland L.J., and Fowler J.M. Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol. Oncol. 102 (2006) 134-139
32. Siu L.L., Awada A., Takimoto C.H., Piccart M., Schwartz B., Giannaris T., et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin. Cancer Res. 12 (2006) 144-151